AMR – Antimicrobial resistance
AMR, which occurs when a microorganism (bacteria, viruses, fungi, parasites) develops the ability to resist the effects of a drug, is a significant global public health threat.
The World Health Organization (WHO), U.S. Government and European Commission each have initiated action plans against AMR. Boosting research, development and innovation—including developing new therapeutics and alternatives—is a key objective of the EU’s One Health Action Plan against AMR.
CYNBIOSE, BIOASTER, ICTA and PharmaLex join forces to launch a pioneering initiative to fast-track antimicrobials from R&D to commercialization :
S.O.L.V.E. AMR
Solutions for Overcoming and Leveraging Versatile Efforts Against Microbial Resistance
This new strategic collaboration aims at supporting the fight against antimicrobial resistance (AMR). As part of the initiative, the organizations offer innovative and integrated support from discovery, pre-clinical and clinical drug development processes up to registration and commercialization, helping to accelerate the development of antimicrobials.
We are delighted to leverage our complementary expertise and capabilities to support innovative AMR solutions.
“In collaboration with our partners, we are delighted to make available our preclinical translational expertise and state-of-the-art BSL2/3 AAALAC-accredited facility to advance innovative therapies such as vaccines, antibodies, immunomodulating candidates and phages to the clinical pipeline”, said Hugues Contamin, CEO of Cynbiose.
Read the press release to learn more.
